Chromatogram Report
04-09-2025 21:03:03 TOSOH 1/1
HEALTH PLUS DIAGNOSTIC PVT. LTD.
Name: Mr. RANJIT BANIK Client Name: 24PGS(N)-XIII Barcode No.: 6522086
PATIENT DETAILS
REPORT DETAILS
CLIENT DETAILS
Age/Gender: 51 Y/Male Client Address: MDDC Collected on: 04/Sep/2025 11:47AM
Lab No: 022509040277
Referred By: Dr. SRINIVASAN K.N Reported on: 04/Sep/2025 07:58PM
Ref Lab/Hospital.: Self @1
Test Name Result Unit Biological Ref.Interval Method
DIABETES SCREENING
Blood Urea Nitrogen (BUN) 13 mg/dL 6 - 20 Calulated
Sample Type:Serum
*Sodium (Na+) 143 mmol/L 135 - 145 Indirect ISE
Sample Type:Serum
*Potassium (K+) 4.02 mmol/L 3.50 - 5.10 Indirect ISE
Sample Type:Serum
Interpratation :
Conditions associated with high potassium values include the following - Hyperlukemia, Blood transfusion, Hemolytic Anemia (red cell destruction), Acute Renal failure, Addison Disease, Hypoaldosteronism, Tissue
injury, Eating disorders (Anorexia, Bulimia), Infection, Diabetic Ketoacidosis, Dehydration, Excessive potassium intake (dietary or intravenous), Magnesium deficiency
Hyperkalemia is defined as a serum potassium concentration greater than the upper limit of the normal range. The range in children and infants is age-dependent, whereas the range for adults is approximately 3.5-5.5
mEq/L. The upper limit may be considerably high in young or premature infants, as high as 6.5 mEq/L. Because hyperkalemia can cause lethal cardiac arrhythmia, it is one of the most serious electrolyte disturbances.
Page 1 of 5
Name: Mr. RANJIT BANIK Client Name: 24PGS(N)-XIII Barcode No.: 6522086
PATIENT DETAILS
REPORT DETAILS
CLIENT DETAILS
Age/Gender: 51 Y/Male Client Address: MDDC Collected on: 04/Sep/2025 11:47AM
Lab No: 022509040277
Referred By: Dr. SRINIVASAN K.N Reported on: 04/Sep/2025 08:02PM
Ref Lab/Hospital.: Self @1
Test Name Result Unit Biological Ref.Interval Method
*Haemoglobin (HGB) 13.9 gm/dL 12.4 - 14.9 Colorimetric Method
Sample Type:Whole Blood EDTA
Page 2 of 5
Name: Mr. RANJIT BANIK Client Name: 24PGS(N)-XIII Barcode No.: 6522086
PATIENT DETAILS
REPORT DETAILS
CLIENT DETAILS
Age/Gender: 51 Y/Male Client Address: MDDC Collected on: 04/Sep/2025 11:47AM
Lab No: 022509040277
Referred By: Dr. SRINIVASAN K.N Reported on: 04/Sep/2025 08:43PM
Ref Lab/Hospital.: Self @1
Test Name Result Unit Biological Ref.Interval Method
*Fasting Blood Glucose (FBS) 111 mg/dL 70 - 110 Hexokinase
Sample Type:Fluoride Plasma
Interpretation :
*A fasting plasma glucose level below 110 mg/dL is considered normal.
*A fasting plasma glucose level between 110-126 mg/dL is considered as glucose intolerant or pre diabetic. A fasting and post-prandial blood sugar test (after consumption of 75 gm of glucose) is recommended for all
such patients.
*A fasting plasma glucose level of above 126 mg/dL is highly suggestive of a diabetic state. A repeat fasting test is strongly recommended for all such patients. A fasting plasma glucose level in excess of 126 mg/dL on
both the occasions is confirmatory of a diabetic state.
Blood Glucose is maintained by a complex interplay of hormones. In diabetes (Both Type I & Type II), various genetic, metabolic and environmental factors lead to progressive loss of Beta Cell Mass or insulin sensitivity,
manifesting as hyperglycemia. Stressful events (eg. Infection, illness, surgery, trauma) too may worsen glycemic control. Any condition leading to deterioration of glycemic control requires more frequent monitoring of
blood glucose.
Reference :
CLASSIFICATION AND DIAGNOSIS OF DIABETES: STANDARD OF MEDICAL CARE IN DIABETES – 2019. Diabetes Care 2019.
*Postprandial Glucose (PP) 188 mg/dL 70 - 140 Hexokinase
Sample Type:Fluoride Plasma
Interpretation :
Blood Glucose is maintained by a complex interplay of hormones. In diabetes (Both Type I & Type II), various genetic, metabolic and environmental factors lead to progressive loss of Beta Cell Mass or insulin sensitivity,
manifesting as hyperglycemia. Stressful events (eg. Infection, illness, surgery, trauma) too may worsen glycemic control. Any condition leading to deterioration of glycemic control requires more frequent monitoring of
blood glucose.
Reference:
CLASSIFICATION AND DIAGNOSIS OF DIABETES: STANDARD OF MEDICAL CARE IN DIABETES-2019. Diabetes Care 2019
*Urea 28 mg/dL 16 - 48 Kinetic UV Assay
Sample Type:Serum
*Creatinine (CREA) 0.91 mg/dL 0.70 - 1.20 Jaffe Kinetic Colorimetric
Sample Type:Serum
Page 3 of 5
Name: Mr. RANJIT BANIK Client Name: 24PGS(N)-XIII Barcode No.: 6522086
PATIENT DETAILS
REPORT DETAILS
CLIENT DETAILS
Age/Gender: 51 Y/Male Client Address: MDDC Collected on: 04/Sep/2025 11:47AM
Lab No: 022509040277
Referred By: Dr. SRINIVASAN K.N Reported on: 04/Sep/2025 08:43PM
Ref Lab/Hospital.: Self @1
Test Name Result Unit Biological Ref.Interval Method
Lipid Profile
*Cholesterol Total (CHOL) 95 mg/dL Desirable: <200 CHOD Enzymetic Colorimetric
Borderline High: 200-239
High: >=240
*Cholestrol (HDL) 27 mg/dL High Risk: <40 Homogeneous Enzymatic
Moderate Risk: 40 - 60 Colorimetric
No Risk: >60
Cholesterol NON HDL 68 mg/dL Calculated
*Triglycerides (TRIG) 155 mg/dL Normal: <150 GPO - PAP
BorderLine: 150-199
High: 200-499
Very High: >=500
Cholesterol (VLDL) 31 mg/dL < 30 Calculated
*Cholesterol LDL 37 mg/dL Optimal: <100 Homogeneous Enzymetic
Above Optimal: 100-129 Colorimetric
Boderline High: 130-159
High: 160-190
Very High: 190
*CHOL Total to CHOL HDL Ratio 3.52 Ratio Low Risk: 3.3 - 4.4 Calculated
Average Risk: 4.5 - 7.0
Moderate Risk: 7.1 - 11.0
High Risk: >=11
Sample Type:Serum
Comment :
Lipid profile checks cholesterol levels, comprising of parameters total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. The results of the lipid profile as per the
AHA guidelines mentioned below, are considered along with other known risk factors of heart disease to develop a plan of treatment and follow-up. A lipid profile typically
includes
-Total cholesterol - this test measures all of the cholesterol in all the lipoprotein particles.
-High-density lipoprotein cholesterol (HDL) -often called "good cholesterol" because it removes excess cholesterol via liver.
-Low-density lipoprotein cholesterol (LDL) -called "bad cholesterol" as it deposits fat and contribute to thickening of blood vessels called atherosclerosis.
Page 4 of 5
Name: Mr. RANJIT BANIK Client Name: 24PGS(N)-XIII Barcode No.: 6522086
PATIENT DETAILS
REPORT DETAILS
CLIENT DETAILS
Age/Gender: 51 Y/Male Client Address: MDDC Collected on: 04/Sep/2025 06:06PM
Lab No: 022509040277
Referred By: Dr. SRINIVASAN K.N Reported on: 04/Sep/2025 09:19PM
Ref Lab/Hospital.: Self @1
Test Name Result Unit Biological Ref.Interval Method
DIABETIC PANEL
HbA1c (Glycosylated Haemoglobin) 6.8 % Normal/Low Risk < 5.7 HPLC
Pre-Diabetes/High Risk Diabetes 5.7 -
6.5%
Diabetes >6.5%
Estimated Average Glucose 148 mg/dL If HBA1c Value 4% - 6% HPLC
Normal 70 - 126
Comment
.
Sample Type:Whole Blood EDTA
REMARKS :
In vitro quantitative determination of HbA1c in whole blood is utilized in long term monitoring of glycemia.The HbA1c level correlates with the mean glucose concentration prevailing in the course of the
patient's recent history (approx - 6-8 weeks) and therefore provides much more reliable information for glycemia monitoring than do determinations of blood glucose or urinary glucose. It is recommended that the
determination of HbA1c be performed at intervals of 4-6 weeks during Diabetes Mellitus therapy. Results of HbA1c should be assessed in conjunction with the patient's medical history, clinical examinations and other
findings.
Test has been performed on Tosho_G8
For test performed on specimens received or collected from non-HPDPL locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the
point generation of the said specimen by the sender. HPDPL will be responsible only for the analytical part of test carried out. All other responsibility will be of referring Laboratory.
*** End Of Report ***
Page 5 of 5
